PRIOR AUTHORIZATION CRITERIA

DRUG CLASS PAIN MANAGEMENT

BRAND NAME (generic)

SAVELLA (milnacipran)

Status: CVS Caremark® Criteria Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Savella is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

• The requested drug is being prescribed for the management of fibromyalgia

AND

• The patient is 18 years of age or older

AND

The request is NOT for continuation of therapy

OR

The request is for continuation of therapy

AND

 The patient has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in pain)

Duration of Approval (DOA):

1345-A: Initial therapy DOA: 6 months; Continuation of therapy DOA: 12 months

REFERENCES

- 1. Savella [package insert]. Madison, NJ: Allergan USA, Inc; December 2022.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed April 24, 2023.Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 04/24/2023).

Savella PA Policy UDR 06-2023.Docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.